BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

OrbiMed raised $3.5 billion across a trio of private funds. The firm has commitments of $1.5 billion for OrbiMed Private Investments VIII, which will invest $10-$100 million in about 40 North American and European biotech,...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 27, 2021
Product Development

The growing pool of gene editing delivery companies

Delivery technologies are likely to rise on the list of business development priorities for gene editing companies as they move into in vivo administration for systemic diseases, and a crop of companies is forming around...
BioCentury | Feb 27, 2021
Distillery Therapeutics

Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression

DISEASE CATEGORY: Cancer INDICATION: Breast cancer An antibody-drug conjugate comprising anti-HER2 antibody trastuzumab linked to POLR2A inhibitor α-amanitin could treat breast cancer with low HER2 expression and heterozygous loss of chromosome 17p. In a panel...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

Anokion S.A. promoted Deborah Geraghty to president and CEO from COO following John Hohneker’s retirement from the Swiss autoimmune company. The company also promoted Raj Manchanda to chief development officer after serving as Anokion’s chief...
BioCentury | Feb 23, 2021
Distillery Therapeutics

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

A £69.2 million ($95.4 million) series C led by Redmile Group gives Evox the funding it needs to bring its internal rare disease pipeline into the clinic as it forges ahead on pharma-partnered programs.  Evox Therapeutics...
Items per page:
1 - 10 of 5593
BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

OrbiMed raised $3.5 billion across a trio of private funds. The firm has commitments of $1.5 billion for OrbiMed Private Investments VIII, which will invest $10-$100 million in about 40 North American and European biotech,...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 27, 2021
Product Development

The growing pool of gene editing delivery companies

Delivery technologies are likely to rise on the list of business development priorities for gene editing companies as they move into in vivo administration for systemic diseases, and a crop of companies is forming around...
BioCentury | Feb 27, 2021
Distillery Therapeutics

Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression

DISEASE CATEGORY: Cancer INDICATION: Breast cancer An antibody-drug conjugate comprising anti-HER2 antibody trastuzumab linked to POLR2A inhibitor α-amanitin could treat breast cancer with low HER2 expression and heterozygous loss of chromosome 17p. In a panel...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

Anokion S.A. promoted Deborah Geraghty to president and CEO from COO following John Hohneker’s retirement from the Swiss autoimmune company. The company also promoted Raj Manchanda to chief development officer after serving as Anokion’s chief...
BioCentury | Feb 23, 2021
Distillery Therapeutics

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

A £69.2 million ($95.4 million) series C led by Redmile Group gives Evox the funding it needs to bring its internal rare disease pipeline into the clinic as it forges ahead on pharma-partnered programs.  Evox Therapeutics...
Items per page:
1 - 10 of 5593